Cue Biopharma is trading at $29.53, down -13.65% after August 14, 2026, Q2 earnings showed a $153.1 million net loss, versus $8.5 million a year earlier.
- EPS was -$24.14, below the reported -$1.38 consensus estimate, while revenue rose to $7.9 million from $3.0 million.
- One-time licensing, acquisition, integration, and non-cash charges drove the unusually large loss.
- The decline is occurring during active trading after a 10.04% gain on August 14.